Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | DRD3 | P35462 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6488829 | 0.98 | NPC1 (0.50) | NPC1JAK2RAB9APAX8KCNH2 | |
| SCHEMBL6484775 | 0.98 | NPC1 (0.50) | NPC1JAK2RAB9APAX8KCNH2 | |
| SCHEMBL6487469 | 0.98 | NPC1 (0.50) | NPC1JAK2RAB9APAX8KCNH2 | |
| SCHEMBL6477185 | 0.98 | NPC1 (0.50) | NPC1JAK2RAB9APAX8KCNH2 | |
| SCHEMBL6477702 | 0.98 | NPC1 (0.50) | NPC1JAK2RAB9APAX8KCNH2 | |
| SCHEMBL449304 | 0.94 | ESR1 (0.46) | NPC1JAK2RAB9APAX8KCNH2 | |
| Hydrochloric Acid SCHEMBL4056298 | 0.92 | ESR1 (0.45) | NPC1JAK2RAB9APAX8KCNH2 | |
| SCHEMBL9717165 | 0.89 | AOC3 (0.45) | KCNH2AOC3TDP1OPRM1DRD3 | |
| SCHEMBL6486956 | 0.86 | SOAT2 (0.42) | NPC1JAK2RAB9APAX8KCNH2 | |
| SCHEMBL6486950 | 0.86 | SOAT2 (0.42) | NPC1JAK2RAB9APAX8KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115894326-A | 2,3-hydrogen substituted aminoindole derivative, preparation method and application thereof | 佛山科学技术学院 | 2023-04-04 | — | — | CN | claimed |
| CN-109467528-B | Synthesis method of 1-aminoindole derivative | 佛山科学技术学院 | 2020-11-06 | — | — | CN | claimed |
| US-4786653-A | Treatment of neurotransmitter-linked drug abuse | GOLWYN DANIEL H (US) | 1988-11-22 | — | — | US | claimed |
| US-11957657-B2 | Combination therapies using immuno-dash inhibitors and PGE2 antagonists | TRUSTEES OF TUFTS COLLEGE (US) | 2024-04-16 | — | — | US | disclosed |
| US-20230390241-A1 | DASH INHIBITORS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE | 2023-12-07 | — | — | US | disclosed |
| US-20230372372-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2023-11-23 | — | — | US | disclosed |
| CN-115894326-A | 2,3-hydrogen substituted aminoindole derivative, preparation method and application thereof | 佛山科学技术学院 | 2023-04-04 | — | — | CN | disclosed |
| US-11583516-B2 | Dash inhibitors, and uses related thereto | TRUSTEES OF TUFTS COLLEGE (US) | 2023-02-21 | — | — | US | disclosed |
| US-11559537-B2 | Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists | TRUSTEES OF TUFTS COLLEGE (US) | 2023-01-24 | — | — | US | disclosed |
| CN-115536716-A | Amphotericin B semisynthetic derivative, preparation method and application thereof | 中国科学院上海药物研究所 | 2022-12-30 | — | — | CN | disclosed |
| CN-109467528-B | Synthesis method of 1-aminoindole derivative | 佛山科学技术学院 | 2020-11-06 | — | — | CN | disclosed |
| EP-0283040-A2 | Silver halide photographic material | FUJI PHOTO FILM CO., LTD. (JP) | 1988-09-21 | — | — | EP | disclosed |
| US-4767692-A | NUCLEATING AGENT WITH UREA AND HYDRAZIDE GROUPS | FUJI PHOTO FILM CO., LTD. (JP) | 1988-08-30 | — | — | US | disclosed |
| EP-0190512-A2 | Positive image forming method | KONICA CORPORATION (JP) | 1986-08-13 | — | — | EP | disclosed |
| US-4550070-A | Direct positive silver halide photographic light-sensitive materials | FUJI PHOTO FILM CO., LTD. (JP) | 1985-10-29 | — | — | US | disclosed |
| US-4160862-A | ANTIINFLAMMATORY | STERLING DRUG INC. (US) | 1979-07-10 | — | — | US | disclosed |
| US-4160862-A | ANTIINFLAMMATORY | STERLING DRUG INC. (US) | 1979-07-10 | — | — | US | disclosed |
| US-4075218-A | INSECTICIDES, FUNGICIDES | ELI LILLY AND COMPANY (US) | 1978-02-21 | — | — | US | disclosed |
| US-4021431-A | ANTIINFLAMMATORY AGENTS | STERLING DRUG INC. (US) | 1977-05-03 | — | — | US | disclosed |
| US-4021431-A | ANTIINFLAMMATORY AGENTS | STERLING DRUG INC. (US) | 1977-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230390241-A1 | DASH INHIBITORS, AND USES RELATED THERETO | CD2BP2, PCNA, CD2 | NPC1 2141/4885JAK2 2296/4885RAB9A 2030/4885 |
| US-11583516-B2 | Dash inhibitors, and uses related thereto | PCNA, CD2BP2, CCNO | NPC1 2242/4885JAK2 2541/4885RAB9A 2161/4885 |
| US-11559537-B2 | Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists | CASP1, CASP2, APAF1 | NPC1 2369/4885JAK2 2101/4885RAB9A 4046/4885 |
| US-20230372372-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | CASP1, CASP2, APAF1 | NPC1 2369/4885JAK2 2101/4885RAB9A 4046/4885 |
| US-11957657-B2 | Combination therapies using immuno-dash inhibitors and PGE2 antagonists | HPGDS, PTGIS, PTGDR2 | NPC1 2802/4885JAK2 2817/4885RAB9A 3160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.